16 completed, 3 unknown, 2 terminated. 21 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 21 | Completed 16, Unknown 3, Terminated 2 |
| Phase 2 | 4 | Completed 2, Terminated 1, Unknown 1 |
Follow Embolism: new trials by email Literature Review of Embolism trials Research Report on Embolism
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacokinetics of Apixaban in Patients Undergoing Pancreaticoduodenectomy Apixaban - Pancreas Cancer, DVT | Phase 1 | Completed | Thomas Jefferson University | 4 | 2020-03-03 | 2021-12-23 |
| A SAD/MAD Study of Safety, Tolerability and Pharmacologic Activity of BT200 in Normal Volunteers BT200, Desmopressin, Placebo - Cerebrovascular Stroke, Large-Artery Atherosclerosis (Embolus/Thrombosis) | Phase 1 | Completed | Band Therapeutics | 112 | 2019-10-07 | 2024-03-18 |
| PET Fibrin Imaging of DVT and PE 64Cu-FBP8, PET-CT imaging - Pulmonary Embolism, Deep Vein Thrombosis | Phase 1 | Terminated | Peter Caravan | 6 | 2019-05-13 | 2026-03-18 |
| First - In - Man Study to Assess the Safety and Feasibility of The Bashir™ Endovascular Catheter for the Treatment of Acute Pulmonary Embolism r-tPA, The Bashir™ Endovascular Catheter - Pulmonary Embolism | Phase 1 | Completed | Thrombolex, Inc. | 9 | 2019-03-14 | 2023-03-30 |
| Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography Ferumoxytol - Pulmonary Embolism | Phase 1 | Completed | Brigham and Women's Hospital | 1 | 2018-09-21 | 2022-07-26 |
| Sidlenafil in Combination With Oral Anticoagulants in Patients With Intermediate-high Risk of Pulmonary Embolism Sildenafil/apixaban, apixaban - Pulmonary Embolism, Intermediate-high Risk | Phase 1 | Unknown | Meshalkin Research Institute of Pathology of Circulation | 100 | 2016-10-01 | 2016-11-01 |
| Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism DS-1040b, Placebo, Enoxaparin - Pulmonary Embolism, Thrombotic Disease | Phase 1 / Phase 2 | Completed | Daiichi Sankyo | 134 | 2016-06-23 | 2023-04-19 |
| Twice Daily Enoxaparin Prophylaxis in Reconstructive Surgery Patients Twice daily enoxaparin prophylaxis, Real time dose adjustment - Venous Thromboembolism, Deep Venous Thrombosis | Phase 1 | Completed | University of Utah | 118 | 2016-03-01 | 2018-10-19 |
| Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery LMWH: Dalteparin, Placebo - Venous Thromboembolism, Lung Neoplasms | Phase 1 / Phase 2 | Completed | McMaster University | 102 | 2015-09-01 | 2018-09-18 |
| Study of Safety and Biomarker Efficacy of TS23 in Healthy Volunteer TS23 - Thrombosis, Cerebral Ischemia | Phase 1 | Unknown | Translational Sciences, Inc. | 24 | 2015-07-01 | 2016-12-23 |
| Bioequivalence Study of Rivaroxaban in Japanese Healthy Adult Male Subjects Rivaroxaban (BAY 59-7939), Rivaroxaban (Xarelto, BAY 59-7939) - Embolism, Atrial Fibrillation and Venous Thrombosis | Phase 1 | Completed | Bayer | 40 | 2014-02-01 | 2015-09-01 |
| Bioequivalence Study of Rivaroxaban Rivaroxaban (BAY 59-7939), Rivaroxaban (Xarelto, BAY 59-7939) - Embolism, Atrial Fibrillation and Venous Thrombosis | Phase 1 | Completed | Bayer | 40 | 2014-01-01 | 2015-09-01 |
| Laparoscopic Bariatric Surgery: Two Regimens of Venous Thromboprophylaxis: Prospective Randomized Study Enoxaparin 40 mg 2 hours before arm, Enoxaparin 40 mg 12 hours before arm - Morbid Obesity, Pulmonary Embolism | Phase 1 / Phase 2 | Unknown | Mansoura University | 700 | 2013-11-01 | 2015-04-08 |
| Comparing Anti-XA Levels in Post-Cesarean Patients Undergoing Enoxaparin Thromboprophylaxis Enoxaparin - Obesity, Obesity, Morbid | Phase 1 | Completed | MemorialCare Health System | 90 | 2013-08-01 | 2015-11-23 |
| Safety Study of the Angel™ Catheter in Subjects With Risk of Pulmonary Embolism Angel Catheter - Pulmonary Embolism, Deep Vein Thrombosis | Phase 1 | Completed | BiO2 Medical | 8 | 2011-12-01 | 2013-05-20 |
| Phase I Trial of Inhaled Nitric Oxide to Treat Acute Pulmonary Embolism nitric oxide - Pulmonary Embolism | Phase 1 | Completed | Wake Forest University Health Sciences | 25 | 2009-02-01 | 2022-04-25 |
| Switching Study From Warfarin to Rivaroxaban Warfarin (Coumadin), Rivaroxaban (Xarelto, BAY59-7939), Placebo - Venous Thrombosis | Phase 1 | Completed | Bayer | 96 | 2008-11-01 | 2015-02-09 |
| Catheter Thrombectomy in Patients With Massive Pulmonary Embolism Mechanical Thrombectomy - Pulmonary Embolism | Phase 1 / Phase 2 | Terminated | Straub Medical AG | 50 | 2005-10-01 | 2009-08-07 |
| Venous Blood Flow Velocity: Electrical Foot Stimulation Compared to Intermittent Pneumatic Compression of the Foot The Focus™ Neuromuscular Stimulation System - Deep Vein Thrombosis, Pulmonary Embolism | Phase 1 | Completed | University at Buffalo | 40 | 2005-06-01 | 2008-03-11 |
| MRI to Detect Embolism Following Angiography and Angioplasty-Stenting of the Renal Artery MRI - Renal Artery Obstruction, Kidney Disease | Phase 1 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 60 | 2001-12-01 | 2008-03-04 |
Showing 20 of 21. Sign in to see all of them.
Pulmonary Embolism (15) · Venous Thrombosis (10) · Venous Thromboembolism (8) · Thrombosis (3) · Atrial Fibrillation (2) · Obesity, Morbid (2) · Atherosclerosis (1) · Brain Ischemia (1) · Embolism, Cholesterol (1) · Hemorrhage (1) · Hypertension, Pulmonary (1) · Hypertension, Renovascular (1) · Intracranial Arteriosclerosis (1) · Kidney Diseases (1)
Cardiovascular Diseases (21) · Embolism and Thrombosis (21) · Vascular Diseases (21) · Lung Diseases (15) · Respiratory Tract Diseases (15) · Thrombosis (9) · Thromboembolism (8) · Pathological Conditions, Signs and Symptoms (5) · Pathologic Processes (4) · Heart Diseases (3) · Arrhythmias, Cardiac (2) · Arterial Occlusive Diseases (2) · Arteriosclerosis (2) · Body Weight (2)
Enoxaparin (4) · Rivaroxaban (3) · Warfarin (2) · apixaban (2) · Dalteparin (1) · Deamino Arginine Vasopressin (1) · Ferrosoferric Oxide (1) · Heparin (1) · Nitric Oxide (1) · Sildenafil Citrate (1) · Tissue Plasminogen Activator (1) · Vitamin K (1) · Vitamin K 1 (1)
Bayer (3) · Band Therapeutics (1) · BiO2 Medical (1) · Brigham and Women's Hospital (1) · Daiichi Sankyo (1) · Mansoura University (1) · McMaster University (1) · MemorialCare Health System (1) · Meshalkin Research Institute of Pathology of Circulation (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · National Institutes of Health Clinical Center (CC) (1) · Peter Caravan (1) · Straub Medical AG (1) · Thomas Jefferson University (1) · Thrombolex, Inc. (1)
United States (11) · Germany (3) · Austria (2) · Japan (2) · Belgium (1) · Canada (1) · Colombia (1) · Egypt (1) · France (1) · Italy (1) · Netherlands (1) · Russia (1) · Spain (1) · Switzerland (1)
Andrew M Siedlecki, MD (1) · Bladimir Gil, MD (1) · Carlos Cadavid, MD (1) · Christopher Pannucci, MD MS (1) · James C Gilbert, MD (1) · James J Czyrny, MD (1) · Jeff A Kline, MD (1) · Jennifer McNulty, MD (1) · Megan L Stephenson, MD (1) · Nils Kucher, MD (1) · Robert E Kaplan, MD (1) · Tilo Winkler, PhD (1) · Ulla Derhaschnig, MD (1)
PMID 24528331, PMID 26658126, PMID 26786296, PMID 29452956, PMID 29608533, PMID 29649055, PMID 31324209, PMID 33356383, PMID 33779986, PMID 34818873, PMID 34818875, PMID 36413425
2008 (1), 2015 (1), R01HL141900 (1)